000739:SHE
Apeloa Pharmaceutical Co Ltd
23,42Â CNÂ¥
arrow_downward
−1,64%(−0,39) 1 p
16. okt, 15:04:48 GMT +8 · CNY
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 000739 põhistatistika genereerimine…
Ava
24,04Â CNÂ¥
Kõrge
24,76Â CNÂ¥
Madal
23,09Â CNÂ¥
Turu kapit.
27,13Â mld
Keskm. maht
16,27Â mln
Maht
15,09Â mln
Dividend
1,61%
Kvartaalne dividend
0,09Â CNÂ¥
Dividendikuupäev
8. okt 2026
Hinna ja tulu suhe
31,78
52 näd kõrgeim
28,50Â CNÂ¥
52 näd madalaim
14,89Â CNÂ¥
Aktsiatulu
0,74Â CNÂ¥
Käibivad aktsiad
1,16Â mld
Töötajate arv
7Â tuh
Ava
24,04Â CNÂ¥
Kõrge
24,76Â CNÂ¥
Madal
23,09Â CNÂ¥
Turu kapit.
27,13Â mld
Keskm. maht
16,27Â mln
Maht
15,09Â mln
Dividend
1,61%
Kvartaalne dividend
0,09Â CNÂ¥
Dividendikuupäev
8. okt 2026
Hinna ja tulu suhe
31,78
52 näd kõrgeim
28,50Â CNÂ¥
52 näd madalaim
14,89Â CNÂ¥
Aktsiatulu
0,74Â CNÂ¥
Käibivad aktsiad
1,16Â mld
Töötajate arv
7Â tuh
Seotud aktsiad
Uudised
Veebiallikatest ja uudistepartneritelt
Yahoo Finance
·
1 tunni eest
SK hynix (NasdaqGS:SKHY) Seeks US Clearance For China Chip Gear Plan
The Motley Fool
·
14 minuti eest
The 10-Year Treasury Is Above 5% for the First Time in Almost 20 Years. History Says This Is How the S&P 500 Index Will Perform Over the Next 12 Months.
Simply Wall Street
·
1 tunni eest
What Ambarella Doubters Saw Before The Drop
Yahoo Finance
·
6 tunni eest
Michael Burry Warns of a Stock Market ‘Supervolcano’
Profiil
Apeloa Pharmaceutical Co., Ltd., known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China. It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997. Apeloa provides contract development and manufacturing services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas.
Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development. It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing. In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development.
Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006. Wikipedia
Teave üksuse Apeloa Pharmaceutical Co Ltd kohta